BiotechTube

PD-1 Inhibitors + Irinotecan + Capecitabine tablets

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

Conditions

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

Trial Timeline

Feb 17, 2023 → Feb 17, 2026

NCT ID
NCT05737563

About PD-1 Inhibitors + Irinotecan + Capecitabine tablets

PD-1 Inhibitors + Irinotecan + Capecitabine tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Esophageal Squamous Cell Carcinoma Abdominal Stage 0. The current trial status is unknown. This product is registered under clinical trial identifier NCT05737563. Target conditions include Esophageal Squamous Cell Carcinoma Abdominal Stage 0.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05737563Phase 3UNKNOWN

Competing Products

20 competing products in Esophageal Squamous Cell Carcinoma Abdominal Stage 0

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
77
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
41
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
52
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPhase 1
33
FamotidineAstellas PharmaPhase 2/3
65
ASP546CAstellas PharmaPhase 1/2
41
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
41
JS001 + nab-paclitaxel + Cisplatin + CarboplatinSun PharmaceuticalPhase 2
52
E3810 + E3810 + PlaceboEisaiPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85